Skip to content

Comparison of Efficacy and Safety of Two Different Types of Laser Therapy for Pigmented Dark Circles

A Comparative Study of the Efficacy and Safety of 1064-nm Nd:YAG Laser and 730-nm Picosecond Laser in Treating Pigmentary Dark Circles: A Randomized, Split-Face Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600126554
Enrollment
Unknown
Registered
2026-06-11
Start date
2026-06-15
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pigmented Periorbital Dark Circles

Interventions

Control group:Q-1064 nm Nd:YAG laser
Experimental group:730 nm Picosecond Laser

Sponsors

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1.Aged 18 to 60 years old (inclusive) with any gender; 2.Patients who was diagnosed with pigmented periorbital dark circles by two experienced physicians; 3.Patients who without any periorbital treatment within 3 months prior to treatment; 4.Patients who signed the informed consent form; 5.Patients who with Fitzpatrick Skin Type ?-?.

Exclusion criteria

Exclusion criteria: 1. Women during pregnancy and lactation; 2. Patients who with periorbital infection or obvious scars; 3. Patients who had a history of any bleeding or coagulation disorders with platelet count < 100×10?/L; 4. Patients who received periorbital cosmetic treatments such as chemical peeling, laser, radiofrequency therapy and injections in the past 3 months; 5. Patients who were allergic to Lidocaine; 6. Any periorbital hyperpigmentation caused by any clinical diseases and other vascular or structural factors; 7. Patients who with application of topical whitening agents within 14 day or photosensitive drugs within 30 days; 8. Patients with systemic hormone use.

Design outcomes

Primary

MeasureTime frame
Effective Clearance Rate;Questionnaire Score of periorbital dark circles;

Secondary

MeasureTime frame
MASI Score of Infraorbital Hyperpigmentation Area;L?a?b? value of periorbital dark circles;Clearance rate of periorbital dark circles;Safety Assessment;

Countries

China

Contacts

Public ContactMa Gang

Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine

docmagang@126.com+86 21 23271699

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 21, 2026